These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 9820411)

  • 21. Effect of sulindac on sporadic colonic polyps.
    Ladenheim J; Garcia G; Titzer D; Herzenberg H; Lavori P; Edson R; Omary MB
    Gastroenterology; 1995 Apr; 108(4):1083-7. PubMed ID: 7698575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sulindac therapy of colorectal polyps in familial adenomatous polyposis.
    Tonelli F; Valanzano R; Dolara P
    Dig Dis; 1994; 12(5):259-64. PubMed ID: 7882547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rectal cancer after prolonged sulindac chemoprevention. A case report.
    Lynch HT; Thorson AG; Smyrk T
    Cancer; 1995 Feb; 75(4):936-8. PubMed ID: 7842414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discouraging colonic polyps.
    Williams CB
    Gut; 1997 Mar; 40(3):430. PubMed ID: 9135538
    [No Abstract]   [Full Text] [Related]  

  • 25. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
    Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
    Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.
    Giardiello FM; Hamilton SR; Krush AJ; Piantadosi S; Hylind LM; Celano P; Booker SV; Robinson CR; Offerhaus GJ
    N Engl J Med; 1993 May; 328(18):1313-6. PubMed ID: 8385741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of an aggressive depressed cancer in a case of familial adenomatous polyposis.
    Saito Y; Fujii T; Akasu T; Gotoda T; Kozu T; Saito D; Sano Y
    Endoscopy; 2002 May; 34(5):421-3. PubMed ID: 11972278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
    Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for hyperplastic and adenomatous polyps: evidence for malignant potential?
    Morimoto LM; Newcomb PA; Ulrich CM; Bostick RM; Lais CJ; Potter JD
    Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1012-8. PubMed ID: 12376501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
    Higuchi T; Iwama T; Yoshinaga K; Toyooka M; Taketo MM; Sugihara K
    Clin Cancer Res; 2003 Oct; 9(13):4756-60. PubMed ID: 14581346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
    Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
    Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Nonsteroidal anti-inflammatory drugs and the risk of polyposis, colon carcinoma and rectal carcinoma].
    Gao X; Sun S; Sun F; Li M; Sun H; Zhang W; Song S
    Zhonghua Yu Fang Yi Xue Za Zhi; 2002 Sep; 36(5):332-5. PubMed ID: 12411196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reducing the risk of recurrent colon polyps.
    Gerner E
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):100-2. PubMed ID: 19367249
    [No Abstract]   [Full Text] [Related]  

  • 34. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
    Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
    Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sulindac in familial adenomatous polyposis.
    Levy R
    N Engl J Med; 2002 Aug; 347(8):615. PubMed ID: 12192027
    [No Abstract]   [Full Text] [Related]  

  • 36. [Efficacy of sulindac in the treatment of rectocolic polyposis].
    Labayle C; Fischer D; Hagege JP
    Gastroenterol Clin Biol; 1986 May; 10(5):436. PubMed ID: 3732747
    [No Abstract]   [Full Text] [Related]  

  • 37. Sulindac for periampullary polyps in FAP patients.
    Richard CS; Berk T; Bapat BV; Haber G; Cohen Z; Gallinger S
    Int J Colorectal Dis; 1997; 12(1):14-8. PubMed ID: 9112144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of piroxicam on prostaglandin E2 levels in rectal mucosa of adenomatous polyp patients: a randomized phase IIb trial.
    Calaluce R; Earnest DL; Heddens D; Einspahr JG; Roe D; Bogert CL; Marshall JR; Alberts DS
    Cancer Epidemiol Biomarkers Prev; 2000 Dec; 9(12):1287-92. PubMed ID: 11142413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac.
    Nugent KP; Spigelman AD; Phillips RK
    Dis Colon Rectum; 1996 Jun; 39(6):659-62. PubMed ID: 8646953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sulindac causes regression of rectal polyps in familial adenomatous polyposis.
    Labayle D; Fischer D; Vielh P; Drouhin F; Pariente A; Bories C; Duhamel O; Trousset M; Attali P
    Gastroenterology; 1991 Sep; 101(3):635-9. PubMed ID: 1650315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.